biotech · Hypertriglyceridemia · Candidiasis, Chronic Mucocutaneous · MTNB
Matinas BioPharma Holdings
Matinas BioPharma is a biotech organization headquartered in Bedminster, USA. It trades on NYSE under ticker MTNB. Primary therapeutic focus areas include Hypertriglyceridemia, Candidiasis, Chronic Mucocutaneous, Cryptoc
Bedminster, USA HQ
2011 Founded
16 Employees
Public company Type
MTNB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bedminster, USA
- Founded
- 2011
- Employees
- 16
- Programs
- 9
- Drugs
- 5
- Patents
- 8
MAT2203
Phase 3 · small molecule · Cryptococcal Meningitis
MAT2203 for Cryptococcal Meningitis is a Phase 3 program (small_molecule) at Matinas BioPharma Holdings with 2 ClinicalTrials.gov record(s).
Internal code MB-70007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Matinas BioPharma Holdings
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Cryptococcal Meningitis
- Status
- active
- Trials
- 2